Cargando…

Base excision repair-mediated resistance to cisplatin in KRAS(G12C) mutant NSCLC cells

KRAS mutations in NSCLC are supposed to indicate a poor prognosis and poor response to anticancer treatments but this feature lacks a mechanistic basis so far. In tumors, KRAS was found to be mutated mostly at codons 12 and 13 and a pool of mutations differing in the base alteration and the amino ac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Caiola, Elisa, Salles, Daniela, Frapolli, Roberta, Lupi, Monica, Rotella, Giuseppe, Ronchi, Anna, Garassino, Marina Chiara, Mattschas, Nikola, Colavecchio, Stefano, Broggini, Massimo, Wiesmüller, Lisa, Marabese, Mirko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4745782/ https://www.ncbi.nlm.nih.gov/pubmed/26353932

Ejemplares similares

Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib
por: Caiola, Elisa, et al.
Publicado: (2018)

Different metabolic responses to PI3K inhibition in NSCLC cells harboring wild-type and G12C mutant KRAS
por: Caiola, Elisa, et al.
Publicado: (2016)

Comparative metabolomics profiling of isogenic KRAS wild type and mutant NSCLC cells in vitro and in vivo
por: Brunelli, Laura, et al.
Publicado: (2016)

Capturing the metabolomic diversity of KRAS mutants in non-small-cell lung cancer cells
por: Brunelli, Laura, et al.
Publicado: (2014)

Glutaminase Inhibition on NSCLC Depends on Extracellular Alanine Exploitation
por: Caiola, Elisa, et al.
Publicado: (2020)

Co-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approach
por: Caiola, Elisa, et al.
Publicado: (2018)

Down-regulation of the Nucleotide Excision Repair gene XPG as a new mechanism of drug resistance in human and murine cancer cells
por: Sabatino, Maria Antonietta, et al.
Publicado: (2010)

Predicting the Role of DNA Polymerase β Alone or with KRAS Mutations in Advanced NSCLC Patients Receiving Platinum-Based Chemotherapy
por: Alvisi, Maria Francesca, et al.
Publicado: (2020)

Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR)
por: Ganzinelli, Monica, et al.
Publicado: (2015)

LKB1: Can We Target an Hidden Target? Focus on NSCLC
por: Ndembe, Gloriana, et al.
Publicado: (2022)

Activity of Birinapant, a SMAC Mimetic Compound, Alone or in Combination in NSCLCs With Different Mutations
por: Colombo, Marika, et al.
Publicado: (2020)

NSCLC Cells Resistance to PI3K/mTOR Inhibitors Is Mediated by Delta-6 Fatty Acid Desaturase (FADS2)
por: Colombo, Marika, et al.
Publicado: (2022)

The 5′UTR variant of ERCC5 fails to influence outcomes in ovarian and lung cancer patients undergoing treatment with platinum-based drugs
por: Rulli, Eliana, et al.
Publicado: (2016)

It’s Got Too Greedy. New Therapeutic Options for Metabolic[ally] Addicted NSCLC?
por: Caiola, Elisa, et al.
Publicado: (2020)

KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy
por: Marabese, Mirko, et al.
Publicado: (2015)

Generation and characterization of MEK and ERK inhibitors- resistant non-small-cells-lung-cancer (NSCLC) cells
por: Iezzi, Alice, et al.
Publicado: (2018)

Single-arm, open label prospective trial to assess prediction of the role of ERCC1/XPF complex in the response of advanced NSCLC patients to platinum-based chemotherapy
por: Ganzinelli, M., et al.
Publicado: (2021)

Treating KRAS-mutant NSCLC: latest evidence and clinical consequences
por: Garrido, Pilar, et al.
Publicado: (2017)

Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC
por: Liu, Weiran, et al.
Publicado: (2016)

Clinicopathologic Characteristics and Outcomes for Patients With KRAS G12D-Mutant NSCLC
por: Cooper, Alissa J., et al.
Publicado: (2022)

Altered Transcriptional Control Networks with Trans-Differentiation of Isogenic Mutant-KRas NSCLC Models
por: Haley, John A., et al.
Publicado: (2014)

Targeted inhibition of glutamine metabolism enhances the antitumor effect of selumetinib in KRAS-mutant NSCLC
por: Xia, Meng, et al.
Publicado: (2020)

LKB1 mutations are not associated with the efficacy of first-line and second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC): a post hoc analysis of the TAILOR trial
por: Vernieri, Claudio, et al.
Publicado: (2020)

Inhibition of lncRNA PART1 Chemosensitizes Wild Type but Not KRAS Mutant NSCLC Cells
por: Chen, Shu-Chen, et al.
Publicado: (2020)

CRISPR-Induced Loss of Connexin 43 Expression Sensitizes KRAS Mutant Cells to Cisplatin
por: Martin, Stephen, et al.
Publicado: (2022)

Efficacy of immunotherapy in KRAS-mutant advanced NSCLC: A real-world study in a Chinese population
por: Peng, Lixiu, et al.
Publicado: (2023)

TEAD Inhibitors Sensitize KRAS(G12C) Inhibitors via Dual Cell Cycle Arrest in KRAS(G12C)-Mutant NSCLC
por: Tammaccaro, Salvina Laura, et al.
Publicado: (2023)

KRAS in NSCLC: State of the Art and Future Perspectives
por: Cascetta, Priscilla, et al.
Publicado: (2022)

A CRISPR screen identifies MAPK7 as a target for combination with MEK inhibition in KRAS mutant NSCLC
por: Dompe, Nicholas, et al.
Publicado: (2018)

Abemaciclib in Combination With Pembrolizumab for Stage IV KRAS-Mutant or Squamous NSCLC: A Phase 1b Study
por: Pujol, Jean-Louis, et al.
Publicado: (2021)

Activity of Pan-Class I Isoform PI3K/mTOR Inhibitor PF-05212384 in Combination with Crizotinib in Ovarian Cancer Xenografts and PDX()
por: Iezzi, Alice, et al.
Publicado: (2016)

Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
por: Adachi, Yuta, et al.
Publicado: (2021)

Implications of KRAS mutations in acquired resistance to treatment in NSCLC
por: Del Re, Marzia, et al.
Publicado: (2017)

Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2019)

Severe Immune Checkpoint Inhibitor Hepatitis in KRAS G12C-Mutant NSCLC Potentially Triggered by Sotorasib: Case Report
por: Begum, Parvin, et al.
Publicado: (2021)

TUSC2 immunogene enhances efficacy of chemo-immuno combination on KRAS/LKB1 mutant NSCLC in humanized mouse model
por: Meraz, Ismail M., et al.
Publicado: (2022)

Inhaled Cisplatin for NSCLC: Facts and Results
por: Kosmidis, Christoforos, et al.
Publicado: (2019)

A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
por: Pang, Xiufeng, et al.
Publicado: (2016)

Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2020)

A Radiogenomics Ensemble to Predict EGFR and KRAS Mutations in NSCLC
por: Moreno, Silvia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5bmg0tr3mcmfarmp0p1kbb4cer